REG-AB Science : The Data and Safety Monitoring Board recommends continuation of the phase 2 study assessing masitinib in relapsing breast cancer

… advanced breast cancer". Breast cancer remains the second most common cancer in … , multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma …